Watson Danielle 4

What Happened

• Danielle Watson, Chief Financial Officer of HeartSciences (HSCS), was granted 25,000 restricted stock units (RSUs) on July 7, 2026. The award is reported as a derivative grant at $0.00 per share (no cash paid at grant). Each vested RSU converts into one share of common stock upon satisfaction of the vesting conditions.

Key Details

• Transaction date: 2026-07-07; Form 4 filed: 2026-07-09 (timely).
• Award: 25,000 RSUs; reported price $0.00; reported as a derivative grant (code A).
• Vesting and conversion: Each RSU settles into one common share when vested (see Conditions).
• Shares owned after the transaction: not specified in the filing.
• Footnotes (summary):
  • F1: RSUs granted under the 2023 Equity Incentive Plan; one RSU = one share on settlement.
  • F2–F3: Vesting is contingent on (i) closing of the merger per the Merger Agreement dated June 22, 2026, and (ii) time-based vesting: 1/4 of the RSUs vest three months after the Closing, then 1/4 each subsequent three-month anniversary, with full vesting at the one-year anniversary, provided continuous employment (subject to certain termination rights).

Context

• This is a compensation award (not a market purchase or sale). RSU grants are common executive pay and do not involve immediate cash or stock changing hands until vesting/settlement conditions are met.
• The award’s value to the insider depends on the occurrence of the referenced merger and subsequent vesting; it does not itself indicate a buy/sell signal for investors.